About Novogene Co., Ltd. Company

The company was incorporated in March 2011 and is committed to becoming the world's leading provider of gene technology products and services. The company has established a high-throughput large-scale gene sequencing platform and a high-performance computing platform, which effectively supports the demand for big data analysis and storage in the two major fields of life science research and healthcare. The company mainly relies on high-throughput sequencing technology and bioinformation analysis technology, has established a gene sequencing platform with leading throughput scale, and combines multi-omics research techniques to provide multi-level scientific research technology services and solutions for basic life science research, medicine and clinical application research; at the same time, it independently develops innovative genetic testing medical devices based on technology accumulation in the field of gene sequencing and its application. The company's products mainly include basic life science research services, medical research and technical services, and library sequencing platform services. Corporate honors: As of June 30, 2023, Novo Zhiyuan has co-signed and published nearly 20,000 SCI articles, with a cumulative impact factor of nearly 120,000. Obtained 62 patents related to genetic sequencing technology and 320 software copyrights.